Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer (NSCLC) * Failed ≥ 1 prior chemotherapy regimen OR refused first-line therapy * Measurable disease * No active and untreated CNS tumor or metastasis * Previously treated CNS tumor(s) allowed if CT scan or MRI shows clear-cut response or resolution of the original lesion(s) PATIENT CHARACTERISTICS: * ECOG performance status 0-1 * Hemoglobin ≥ 9.0 g/dL * WBC ≥ 2,500/mm\^3 * Absolute neutrophil count ≥ 1,000/mm\^3 (growth factor independent) * Platelet count ≥ 100,000/mm\^3 * Total bilirubin ≤ 1.5 mg/dL * AST and ALT ≤ 3 times upper limit of normal (ULN) (5 times ULN if patient has liver metastases) * Alkaline phosphatase ≤ 5 times ULN * Serum creatinine ≤ 2.0 mg/dL * PT/PTT normal * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective (double barrier or abstinence) contraception * No uncontrolled seizure disorder or active neurological disease * No thromboembolic events (i.e., stroke or deep vein thrombosis) within the past year * No clinically significant medical condition that would complicate compliance with study treatment or be exacerbated by bleeding, including but not limited to: * Known bleeding disorders, such as coagulation defects and thrombasthenias * Active gastric or duodenal ulcer * History of gastrointestinal (GI) bleeding requiring transfusion within the past year * History of tumor bleeding * History of significant hemoptysis requiring intervention (i.e., transfusion, laser therapy, surgical treatment, or radiation) within the past year * No known active infections requiring IV antibiotics, antivirals, or antifungals (e.g., HIV, hepatitis B, or hepatitis C infection) * No unstable cardiac disease, including any of the following: * Poorly controlled angina * Congestive heart failure * Arrhythmias * Myocardial infarction within the past year * Acute ischemia by ECG * Untreated significant conduction abnormality * Bifascicular block (defined as left anterior hemiblock in the presence of right bundle branch block) * Second- or third-degree atrioventricular block * No asthma or oxygen-dependent chronic pulmonary disease * No cerebrovascular event (e.g., stroke or transient ischemic attack) within the past year * No peripheral vascular disease requiring surgery within the past year * No clinically significant or unstable medical condition, including, but not limited to, any of the following: * Diabetes mellitus requiring insulin * Uncontrolled hypertension * Uncontrolled or symptomatic orthostatic hypertension * No serious psychiatric illness, active alcoholism, or drug addiction that may preclude study treatment * No condition that, in the investigator's opinion, would make the patient unsuitable for study treatment PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Prior immunotherapy, including monoclonal antibodies, or vaccine therapy allowed * No systemic biologic, immunotherapy, or radiation therapy within the past 4 weeks * Local radiotherapy to a single site of bone metastasis within the past 2 weeks allowed provided patient has recovered from any side effects * No prior volociximab, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, or inhibitors of α5β1 integrin (antibodies or small molecules) * No known hypersensitivity to murine proteins or chimeric antibodies or other components of study drugs * No other investigational drug within the past 4 weeks or 5 half-lives (whichever is longer) * No monoclonal antibody therapy within the past 4 weeks or 5 half-lives (whichever is longer) * No major surgery (e.g., thoracotomy) within 4 weeks prior to study entry * No minor surgery (e.g., central venous line placement) within 1 week prior to study entry * No sargramostim (GM-CSF) or filgrastim (G-CSF) within the past 7 days * No prior bone marrow or stem cell transplantation * No concurrent chronic medications that would interfere with study drug assessment including, but not limited to: * High-dose glucocorticoids (prednisone ≥ 20 mg/day or equivalent) * Chronic nonsteroidal anti-inflammatory drugs (NSAIDs) * Infrequent or as occasion requires use of NSAIDs allowed * No concurrent high-dose aspirin (\> 81 mg/day), high-dose warfarin, or heparin * Aspirin ≤ 81 mg/day, low-dose warfarin (1 mg/day), or low-dose heparin for IV-catheter patency allowed * No concurrent chemotherapy, therapeutic radiation, or anticancer hormonal therapy * No other concurrent immunotherapy * No other concurrent potentially antiangiogenic therapy (e.g., cyclo-oxygenase-2 inhibitors, thalidomide, or tretinoin)